TVRD SECURITIES ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Core Points - Tvardi Therapeutics, Inc. experienced a significant decline in its stock price, dropping over 80% following disappointing preliminary data from its Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis [5] Group 1: Company Overview - Tvardi Therapeutics, Inc. is listed on NASDAQ under the ticker TVRD [2] - The company is currently under investigation for potential claims related to its stock performance [2] Group 2: Clinical Trial Results - The Phase 2 REVERT clinical trial aimed to evaluate safety, pharmacokinetics, and exploratory outcomes related to lung function [5] - Preliminary data indicated that the trial did not meet its goals, with changes in Forced Vital Capacity (FVC) being a key focus [5] - Patients' baseline characteristics were similar across treatment arms, except for a lower percent predicted FVC in the placebo group compared to the TTI-101 group [5]